Business Description
Abivax SA
ISIN : FR0012333284
Compare
Compare
Traded in other countries / regions
ABVX.USAABVX.France2X1.Germany0RA9.UK IPO Date
2016-09-27Description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.71 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -0.42 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.3 | |||||
| 3-Year EPS without NRI Growth Rate | -6.5 | |||||
| 3-Year FCF Growth Rate | -1.8 | |||||
| 3-Year Book Growth Rate | 35.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 99.92 | |||||
| 6-1 Month Momentum % | -11.41 | |||||
| 12-1 Month Momentum % | -31.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.08 | |||||
| Quick Ratio | 4.08 | |||||
| Cash Ratio | 3.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.8 | |||||
| Shareholder Yield % | -37.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -156.24 | |||||
| ROA % | -77.26 | |||||
| ROIC % | -229.33 | |||||
| ROC (Joel Greenblatt) % | -15040.88 | |||||
| ROCE % | -94.46 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.87 | |||||
| Price-to-Tangible-Book | 5.59 | |||||
| EV-to-EBIT | -5.6 | |||||
| EV-to-Forward-EBIT | -5.25 | |||||
| EV-to-EBITDA | -5.63 | |||||
| EV-to-Forward-EBITDA | -5.32 | |||||
| EV-to-Forward-Revenue | 576.59 | |||||
| EV-to-FCF | -7.7 | |||||
| Price-to-Net-Current-Asset-Value | 6.16 | |||||
| Price-to-Net-Cash | 7.32 | |||||
| Earnings Yield (Greenblatt) % | -17.86 | |||||
| FCF Yield % | -10.2 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers